🔎 Trials Near Me

Почетна › Рак бубрега (карцином бубрежних ћелија) › Тексас

Kliničke studije za Рак бубрега (карцином бубрежних ћелија) u državi Тексас

57 studija za Рак бубрега (карцином бубрежних ћелија) traži učesnike na lokacijama u državi Тексас.

Gradovi u državi Тексас

Zvanični tekst studije (na engleskom)

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

  • The University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT06805825

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

  • UT Southwestern Medical Center ( Site 0119), Dallas
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT07489495

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

  • Research Site, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT05536141

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
  • и још 1
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT03866382

Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

  • MD Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07023432

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

  • NEXT Austin, Austin
  • START Center for Clinical Research, Fort Worth
  • University of Texas MD Anderson Cancer Center, Houston
  • и још 2
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06270706

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

  • The University of Texas M. D. Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT07187778

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • The University of Texas Health Science Center at Tyler, Tyler
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT04198766

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • The Don and Sybil Harrington Cancer Center, Amarillo
  • UT MD Anderson Cancer Center, Houston
  • Audie L Murphy VA Hospital, San Antonio
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

  • MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT03972657

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

  • NEO-811 Dallas Site, Dallas
  • NEO-811 Houston Site, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07300241

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

  • MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT05663710

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

  • University of Texas Southwestern Medical Center, Dallas
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT05856981

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  • The Don and Sybil Harrington Cancer Center, Amarillo
  • Houston Methodist San Jacinto Hospital, Baytown
  • Houston Methodist Cypress Hospital, Cypress
  • и још 14
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06661720

Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

  • University of Texas Southwestern Medical Center, Dallas
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06601296

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

  • UT MD Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 12 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT04981509

A Study of MGC026 in Participants With Advanced Solid Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
  • University of Texas Health Science Center at Houston, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06242470

Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)

  • UT Southwestern Medical Center, Dallas
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT05931393

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

  • Parkland Memorial Hospital, Dallas
  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • и још 3
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT05327686

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

  • START San Antonio, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT06582017

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

  • UT Southwestern Simmons Cancer Center, Dallas
  • MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT06026410

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

  • Clinical Trial Site, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT07749586

Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma

  • UT MD Anderson, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT07564232

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

  • Md Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT07195916

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  • Texas Oncology - Central South, Austin
  • Texas Oncology - Central South, Austin
  • Texas Oncology - Central South, Austin
  • и још 26
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07227415

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
  • и још 4
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT04510597

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

  • Research Site, Houston
  • Research Site, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07115043

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

  • Texas Oncology, Dallas
  • University of Texas Southwestern Medical Center, Dallas
  • University Medical Center & Texas Tech Health Science Center, Lubbock
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 2. 10. 2026. · NCT06234605

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #46, Austin
  • Exelixis Clinical Site #89, Dallas
  • Exelixis Clinical Site #73, Irving
  • и још 2
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT05176483

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

  • University of Texas - MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT05287945

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

  • The University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT07594106

DESTINY-PANTUMOUR04

  • Research Site, Dallas
Тражи се учесникОпсервациона студија
Узраст од 18 до 130 · Оба пола · Ажурирано 25. 9. 2026. · NCT07124000

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

  • Baylor, Scott and White Research Institute, Dallas
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 24. 9. 2026. · NCT06047379

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

  • M D Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 18. 9. 2026. · NCT05048212

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

  • Texas Oncology (Balcones) - SCRI, Austin
  • MD Anderson Cancer Center, Houston
  • START South Texas Accelerated Research Therapeutics, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 18. 9. 2026. · NCT05267626

Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

  • University of Texas Southwestern Medical Center, Dallas
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT05319015

TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma

  • The University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 15. 9. 2026. · NCT04969315

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • UT Southwestern Medical Center, Dallas
  • DHR Health Advance Care Center, Edinburg
  • The Center for Cancer and Blood Disorders, Forth Worth
  • и још 1
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 14. 9. 2026. · NCT05059444

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

  • Mary Crowley Cancer Research, Dallas
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 9. 9. 2026. · NCT06750185

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

  • MD Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 20. 8. 2026. · NCT06940518

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.